Assistant Professor, Leukemia Department
Oncology
Dr. Tapan M. Kadia, MD
|
|
Give Review
Tapan Kadia practices Oncology. He attended Rutgers Robert Wood Johnson Medical School. Rutgers Robert Wood Johnson Medical School has a rank of 74 in research and a 67 in primary care Tapan M. Kadia is also a published doctor. He has 75 publication published. The most recent publication is: Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Analysis of 2013 European LeukaemiaNet (ELN) responses in Chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
- Clinical implications of TP53 mutations in myelodysplastic Syndromes treated with hypomethylating agents.
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a single-centre, phase...
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- Prognostic factors for outcome in patients with refractory and relapsed Acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in Acute myeloid ...
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Incidence of secondary neoplasms in patients with Acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid p...
- Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory Acute lymphoblastic leukemia.
- Outcome of patients with low-risk and intermediate-1-risk myelodysplastic Syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
- Progress in Acute Myeloid Leukemia.
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant Anemia.
- Recent Developments in Drug Therapy for Aplastic Anemia.
- The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic Syndromes.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia.
- Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic Leukemia post clofarabine failure.
- Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with Acute myeloid leukemia treated with hypomethylating agents.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic Syndromes.
- Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics.
- Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell Acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndrom...
- Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic Syndrome is associated with poor prognosis and transformation to acut...
- Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia.
- Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- Modest activity of pomalidomide in patients with myelofibrosis and significant Anemia.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced Myeloid malig...
- Prognostic impact of RAS mutations in patients with myelodysplastic Syndrome.
- Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in Acute leukemic phase.
- Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic Syndrome: A retrospective case-control study.
- Clinical and proteomic characterization of Acute myeloid leukemia with mutated RAS.
- Prognostic significance of 11q23 aberrations in adult Acute myeloid leukemia and the role of allogeneic stem cell transplantation.
- FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic Leukemia.
- Predicting survival of patients with hypocellular myelodysplastic Syndrome: development of a disease-specific prognostic score system.
- Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with Acute myeloid leukemia.
- Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive Acute lymphoblastic leukaemia.
- Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
- Phase I-II study of bendamustine in patients with Acute leukemia and high risk myelodysplastic syndrome.
- Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory Acute myeloid leukemia.
- Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype Acute myelogenous leukemia.
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
- Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplast...
- Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High...
- Hypocellular Acute myeloid leukemia in adults: clinical outcome analysis of 123 patients.
- Failure of hypomethylating agent-based therapy in myelodysplastic Syndromes.
- Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting ...
- Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic Syndrome.
- Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid Leukemia.
- Persistence of cytogenetic abnormalities at complete remission after induction in patients with Acute myeloid leukemia: prognostic significance and the potential role ...
- Nilotinib as front-line treatment for patients with chronic myeloid Leukemia in early chronic phase.
- Dapsone induced methemoglobinemia in a patient with glioblastoma.
- Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative Acute lymphocytic leukemia.
- The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antiLeukemia activity by activating both apoptosis and autophagy.
- Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor Acute myeloid leukemia: more than meets the eye.
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with Acute myeloid leukemia.
- The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antiLeukemia activity by activating both apoptosis...
- A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
- Differential coupling of serotonin 5-HT1A and 5-HT1B receptors to activation of ERK2 and inhibition of adenylyl cyclase in transfected CHO cells.
- Role of epigenetic therapy in myelodysplastic Syndrome.
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Schools
UmdnjRobt W Johnson Med Sch
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Aortic Embolism and Thrombosis
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Baylor College of Medicine -
Rutgers Robert Wood Johnson Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1083703698 | |
| NPPES Provider LastName | KADIA | |
| NPPES Provider FirstName | TAPAN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 820.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 2.32 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083703698 |
| Last Name Of The Provider | KADIA |
| First Name Of The Provider | TAPAN |
| View All |
Similar Doctors
|
|
Dr. Wenli Liu, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hector A. Preti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Lehane, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John C. Araujo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Falchook, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Hesham M. Amin, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kanza S. Abbas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John V. Heymach, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|